Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.57 USD | +0.78% | +9.36% | -19.18% |
Jun. 04 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
May. 15 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.18% | 20.86M | |
+48.54% | 56.61B | |
+36.61% | 39.25B | |
-6.02% | 39.62B | |
-6.90% | 28.28B | |
+12.97% | 26.44B | |
-16.91% | 20.12B | |
+31.71% | 12.48B | |
+28.18% | 12.51B | |
+0.38% | 12.2B |
- Stock Market
- Equities
- LUMO Stock
- News Lumos Pharma, Inc.
- Cantor Fitzgerald Adjusts Lumos Pharma's Price Target to $10 From $14, Keeps Overweight Rating